Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI (CONTRAST-2)

Assessment of the Effects of Long-term Lipid-lowering Therapy on Parameters of Electrical Myocardial Heterogeneity, Myocardial Deformation Characteristics, Vascular Rigidity, and Quality of Life in Patients With Primary STEMI or NSTEMI

In a single-center, open-label, prospective, controlled, clinical study, it is planned to include 300 patients hospitalized in the cardiology department of SBHI Penza regional clinical hospital n.a. N.N. Burdenko. Recruitment of patients will be carried out at the Department of Therapy of the Medical Institute of the Penza State University. Patients meeting the inclusion criteria and not meeting the exclusion criteria will be included in the study.

Initially, lipid-lowering treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy.

If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.

Standard AMI treatment includes dual antiplatelet therapy, ACE inhibitors, beta-blockers (if indicated). Prescription of proton pump inhibitors and nitrates is possible (if indicated).

The total follow-up is 96 weeks. Prescreening - 600 people; screening and randomization - 300 people. Parameters of electrical myocardial heterogeneity, myocardial deformation characteristics, vascular rigidity, and quality of life will be assessed according to the study plan.

Study Overview

• Status: Recruiting
• Conditions: Quality of Life; Arterial Stiffness; Myocardial Infarction, Acute; Myocardial Strain
• Intervention / Treatment: Drug: Atorvastatin 80mg

Detailed Description

Methods

1. Blood chemistry test. Total cholesterol, LDL, HDL, triglycerides, AST, ALT, CPK, glucose, CRP, creatinine, glycosylated hemoglobin

2. 2D and 3D transthoracic echocardiography (Vivid GE 95 Healthcare (USA). 3D speckle echocardiography (3DSTE) for a detailed study of the phase-by-phase movement and spatial interaction of all muscle layers of the left ventricle in different phases of the cardiac cycle to obtain quantitative values of the deformation of the left ventricle individual segments in the longitudinal, circumferential and radial directions.

   The analysis of standard indicators of echocardiography: biplane ejection fraction according to the Simpson method, 3D ejection fraction, EDV (end-diastolic volume), ESV (end-systolic volume) and their indices. The left ventricular myocardial mass index (LVMI).

   Using a tissue doppler, the parameters characterizing the diastolic function are recorded: the LA volume, the early diastolic velocity of the mitral valve fibrous ring, the ratio of the early diastolic transmitral flow E to the average early diastolic speed of the fibrous ring e´, and the maximum tricuspid regurgitation rate.

   Myocardial strain is analyzed using specialized software - EchoPac Software Only (General Electric Co., 2018). For three-dimensional strain analysis, the left ventricle is automatically divided into 17 segments using standard segmentation schemes. The software allows obtaining strain values in the endocardial, middle and epicardial layers of the myocardium. Over a period of time, indicators for each segment are automatically calculated:

   longitudinal strain/strain rate (LS,%/LSR, cm / s-1), circumferential strain/strain rate (CS,%/CSR, cm / s-1), radial strain/strain rate(RS,%/RSR, cm / s-1), area strain), rotation, rotation along the axis of the left ventricle (Torsion).

3. Long-term ECG monitoring over 3 leads with an assessment of the parameters of myocardial electrical instability A long-term ECG recording (120 hours) in patients with myocardial infarction will be performed using the Astrocard ECG system (CJSC Meditek, Russia) with 3-channel recorders. Long-term recordings will be analyzed separately for 3 time intervals: 24, 72 and 120 hours.

   Pauses of rhythm, rhythm disturbances - extrasystole, unstable tachycardia, AF paroxysm and atrial flutter, ventricular fibrillation, conduction disturbance will be recorded.

   Assessment of the ST segment dynamics will be carried out with detection of ischemia episodes, which will be detected when the ST segment is displaced ≥10 mV from the baseline 80 ms after the J point for at least 1 min - episodes of elevation and depression of the ST segment.

   According to the long-term ECG monitoring recordings, the following parameters will be analyzed (separately for 3 intervals - 24, 72 and 120 hours):

   circadian dynamics of heart rate; late ventricular potentials (LVP); variance and duration of the QT interval; heart rate variability (HRV); heart rate turbulence (TCP); chronotropic load (CL). Circadian dynamics of heart rate. The circadian dynamics of heart rate will be analyzed with an estimate of the minimum, average and maximum heart rate per day, during waking hours and night sleep. The circadian index (CI) will be defined as the ratio of the average heart rate in the daytime and the average heart rate in the night.

   LVP. The LVP will be evaluated in the standard averaging mode in the range of 40-100 Hz by the noise level not exceeding 0.9 μV. Records of the 24-h ECG in patients who have a decrease in intraventricular conduction, bundle branches blockade, will not be subjected to LVP analysis. An automatic analysis of late post-depolarization begins with a search for the QRS reference complex, which will be used later as a reference for averaging. Subsequently, the ECG signal will be processed programmatically by the time analysis method, at the end of which the following parameters will be evaluated: the width of the filtered QRS complex (QRSf), the duration of the low-amplitude potentials at the end of the QRS complex of the final part of the complex (HFLA), the rms value of the last 40 ms QRS (RMS ) Dispersion and QT interval duration. For a detailed study of the repolarization process in the analysis of records, close attention will be paid to the analysis of the duration, variability and variance of the QT interval.

   HRV. The following HRV time indicators will be considered:

   • Mean NN (ms) - average value of all RR-intervals;
   • SDNN (ms) - standard deviation of the average values of RR-intervals;
   • SDNNi (ms) - average value of standard deviations RR for 5-minute recording periods;
   • SDANN (ms) is the standard deviation of the mean values of the sinus intervals RR for 5 min;
   • rMSSD (ms) is the square root of the sum of the differences of subsequent RR intervals;
   • pNN50 (%) is the percentage of successive RR intervals differing by more than 50 ms;
   • HRVti - triangular index;
   • TINN is the index of triangular interpolation of the histogram of RR-intervals.

   HRV frequency parameters:

   • TotP (ms2) is the power of the total spectrum;
   • ULfP (ms2) - spectrum power in the ultralow frequency range;
   • VLfP (ms2) is the power of the spectrum within very low frequencies;
   • LfP (ms2) - low-frequency range of frequencies; HfP (ms2) - high-frequency component of HRV; L / H - an indicator of the balance of the vagosympathetic balance. Evaluation of the above HRV parameters will be carried out per day, night and day hours.

   TCP is characterized by two independent parameters - the beginning of turbulence (TO) and the slope of turbulence (TS).

   Heart CL is assessed by the level and duration of exceeding the actual (observed in the patient during monitoring) heart rate values of the threshold heart rate calculated individually according to the proposed formulas with differentiation for periods of wakefulness and night sleep:

   THR-W (bpm) = HRmax (bpm) × 0.45, where THR-W is the threshold value of the heart rate during wakeful hours in beats per minute, heart rate max is the age-appropriate value of the maximum possible heart rate in beats per minute, 0.45 is the coefficient of the threshold level of heart rate; THR-S (bpm) = THR-W (bpm): 1.24, where THR-S (bpm) is the threshold value of the heart rate during the night's sleep.

4. Ultrasound of the common carotid arteries with RF high frequency signal technology The study of local vascular stiffness by high-frequency RF signal technology using ultrasound of the common carotid arteries (CCA) will be carried out in B mode using MyLab 90 (Esaote, Italy).

   The RF signal technology includes two programs: RF-QIMT and RF-QAS. The following CCA indicators are analyzed: IMT - intima-media thickness, loc Psys - local systolic pressure in the carotid artery, loc Pdia - local diastolic pressure, P (T1) - pressure at the local point, stiffness indices β and α, DC is the coefficient of lateral distensibility, CC - coefficient of lateral compliance, Aix is the augmentation index, AP is the amplification pressure, PWV is the local pulse wave velocity in the carotid artery.

5. Ultrasound of the brachiocephalic and femoral arteries The brachiocephalic and femoral arteries will be scanned using a Vivid GE 95 ultrasound scanner (Healthcare, USA) using a linear sensor in B-mode, spectral Doppler imaging and color Doppler imaging.

   Quantitative analysis of atherosclerotic plaque includes determining the extent and degree of narrowing of the lumen of the vessel (percentage of stenosis) by the cross-sectional area (Sa) of the vessel:

   Sa = (A1 - A2) × 100% / A1, where A1 is the true cross-sectional area of the vessel, A2 is the passable cross-sectional area of the vessel.

6. Applanation tonometry. SphygmoCor apparatus (AtCor Medical, Australia) uses pulsed wave to calculate the characteristics of central pressure in aorta.

   The applanation tonometry technique includes two programs: PWA and PWV. The first allows to record central aortic pressure indicators: systolic aortic pressure - SBPao, diastolic - DBPao, pulse - PPao, mean hemodynamic - MBPao based on registration of the radial artery PWV. Using the PWV program, sequential recording of PWV from the common carotid and femoral arteries simultaneously with the ECG channel analyzes the PWV in the aorta (cfPWV).

7. Volume sphygmography. The measurements will be carried out with the VS-1000 device (Fukuda Denshi, Japan) while simultaneously recording plethysmograms on four limbs (using cuffs), ECG, phonocardiogram, and PWV on the carotid and femoral arteries.

   PWV is evaluated in different parts of the circulatory system (i.e., aorta (PWV), predominantly elastic arteries (R/L-PWV) and predominantly muscular arteries (B-PWV)).

   Cardio-Ankle Vascular Index (CAVI) is determined - an indicator that reflects the true stiffness of the vascular wall. CAVI is calculated by registering PWV at two points and measuring SBP and DBP. Additionally augmentation index and biological age will be calculated automatically.

8. Flow-mediated dilation. Endothelial function is evaluated by ultrasonic determination of flow-mediated dilation (FMD) during the postocclusive reactive hyperemia test using the method described by D. Celenmajer et. al.
9. Six-minute walk (6MW) test. The patient should not take cardiological drugs and should not smoke within at least 2 hours before the test. Before the 6MW test, the patient should have a 10-minute quiet rest in a sitting position. During this rest period, the following text should be read to the patient: "You will have to walk for 6 minutes, without using continuous running or alternate running and walking, with the aim to cover a maximum distance. You will walk back and forth along the corridor. You can slow down the pace, stop and have a rest in case of dyspnea or weakness. You can lean against the wall during rest. Then, you will have to resume the walk. Remember that your aim is to cover maximum distance in 6 minutes." At the 6-minute time point, the patient should be asked to stop and stand still until the covered distance has been measured.
10. Computer Pulse Oximetry. During the 6-minute walk test, computer pulse oximetry is planned on a PulseOx 7500 instrument (SPO medical, Israel) to study saturation dynamics in comparison groups.
11. Treatment compliance will be evaluated by standard methods (counting the remaining tablets). Morisky-Green Questionnaire
12. Quality of Life Assessment. The following questionnaires are planned to be completed: Seattle Angina Questionnaire (SAQ), Minnesota Questionnaire, Clinical Assessment Scale for CHF (MQCAS) (modified by Mareev VY, 2000), analog-visual scale.
13. Assessment of physical activity. It is planned to fill out a questionnaire for assessing the level of physical activity and a short international questionnaire for determining the physical activity of the International Questionnaire On Physical Activity - IPAQ
14. Assessment of Anxiety Depression. An analysis of anxiety and depressive disorders in patients using the hospital scale of anxiety and depression (HADS) is planned

• Study Type: Interventional
• Enrollment (Anticipated): 300
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Nadezhda V Burko, PhD; Phone Number: +78412548229; Email: hopeful.n@mail.ru

Study Locations

• Russian Federation
  • Penza, Russian Federation, 440026
    • Recruiting
    • Valentin Oleynikov

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Signed Informed Consent Form 2 Primary STEMI or NSTEMI confirmed by ECG, troponin I and CPK-MB levels, coronary angiography.

3. Presence of an infarct-related artery according to coronary angiography.

Exclusion Criteria:

1. Presence of hemodynamically relevant stenosis exceeding 30% in several coronary arteries confirmed by CAG;
2. Recurrent or repeated myocardial infarction.
3. Exogenous hypertriglyceridemia (type 1 hyperchilomicronemia).
4. The development of acute heart failure III-IV prior to randomization
5. Individual intolerance to statins, ezetimibe.
6. Congenital and acquired heart diseases.
7. Severe concomitant diseases in the stage of decompensation.
8. Non-sinus rhythm, established artificial pacemaker.
9. Sinoatrial and atrioventricular blockade of 2-3 degrees.
10. QRS complex exceeding 100 ms.
11. The presence of severe LV hypertrophy according to echocardiography.
12. Uncontrolled hypertension with SBP> 180 mm Hg and DBP> 110 mmHg
13. Diabetes mellitus (DM) type 1 and 2.
14. Current existence of severe anemia (Hb < 100 g/L)
15. Chronic kidney disease (creatinine clearance less than 30 ml / min / 1.73 m2 according to the CKD-EPI).
16. Non-corrected thyroid dysfunction with hyper / hypothyroidism.
17. Body mass index (BMI) ≥35 kg / m2.
18. Pregnancy, lactation.
19. Alcohol abuse, drug addiction.
20. Other serious concomitant diseases that exclude the possibility of study participation.
21. Participation in other clinical trials within the last two months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Atorvastatin 80 mg; Treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy. If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.	Drug: Atorvastatin 80mg; Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy; Other Names: Ezetimibe
ACTIVE_COMPARATOR: Atorvastatin-Ezetimibe; In the absence of reaching the target level of LDL-C of ≤1.4 mmol / L and a decrease in the indicator by ≥50% after 5-6 weeks from the onset of AMI, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.	Drug: Atorvastatin 80mg; Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy; Other Names: Ezetimibe

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ventricular arrhythmias	Statistically significant differences in the frequency of ventricular arrhythmias as compared to controls	up to 48 months
Systolic function	Statistically significant differences in systolic function of the left ventricle according to transthoracic echocardiography as compared to controls;	up to 48 months
Myocardial deformation of the LA and LV	Statistically significant differences in the myocardial deformation of the LA and LV as compared to controls	up to 48 months
PCI / CABG for a new case of coronary atherosclerosis, hospitalization for unstable angina	Statistically significant differences for major coronary events - PCI / CABG for a new case of coronary atherosclerosis, hospitalization for unstable angina as compared to controls	up to 48 months
Myocardial electrical instability	Statistically significant differences in the late ventricular potentials, heart rate variability, QT interval dispersion (ms) as compared to controls	up to 120 hours for 2 years period
Heart rate turbulence	Statistically significant differences in the parameters of heart rate turbulence (%) as compared to controls	up to 120 hours for 2 years period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cardiovascular mortality	Statistically significant differences for incidence of CV events as compared to controls	up to 48 months
Frequency of repeated fatal / non-fatal MI	Statistically significant differences in the frequency of repeated fatal / non-fatal MI as compared to controls	up to 48 months
Hospitalization due to acute decompensation of heart failure	Statistically significant differences according to the frequency of hospitalization due to acute decompensation of heart failure as compared to controls	up to 48 months
Structural state of arteries different types	Statistically significant differences in pulse wave velocities in arteries of various calibers, as compared to controls	up to 48 months
Structural state of carotid artery	Statistically significant differences in intima-media thickness of carotid artery according ultrasound, as compared to controls	up to 48 months
Functional state of arteries	Statistically significant differences in flow-mediated dilation parameters (diameter of brachial artery, mm) assessed by ultrasound, as compared to controls	up to 48 months
Progression of CHF, exercise tolerance	Statistically significant differences in 6-minute walk test (distance covered, m), as compared to controls	up to 48 months
Progression of CHF, laboratory data	Statistically significant differences in BNP level (pg/ml), as compared to controls	up to 48 months
Left ventricular remodeling	Statistically significant differences echocardiographic parameters of left ventricle pathological remodeling (ejection fraction, %, EDVi, ESVi) as compared to controls	up to 48 months
Lipid profile	Statistically significant differences of lipid profile (mmol/l) as compared to controls	up to 48 months
Laboratory parameters	Statistically significant differences of CRP (mg/l) as compared to controls	up to 48 months
Angina episodes	Statistically significant differences on angina episodes assessed by Seattle Angina Questionnaire (min - 19, max - 108 better outcome), as compared to controls	up to 48 months
Quality of life questionnaire	Statistically significant differences according to the quality of life of patients assessed by Minnesota Questionnaire (min -0, max-105, worse outcome), as compared to controls	up to 48 months
Quality of life questionnaire in СHF	Statistically significant differences according to the quality of life of patients assessed by Clinical Assessment Scale for CHF(min -0, max-20, worse outcome), as compared to controls	up to 48 months
Patients wellbeing	Statistically significant differences of patients wellbeing according to the analog-visual scale , as compared to controls	up to 48 months

Collaborators and Investigators

• Sponsor: Penza State University
• Investigators: Principal Investigator: Valentin E Oleynikov, DM, Penza State University

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 12, 2020
• Primary Completion (ANTICIPATED): September 12, 2022
• Study Completion (ANTICIPATED): December 30, 2022

Study Registration Dates

• First Submitted: March 20, 2020
• First Submitted That Met QC Criteria: April 12, 2020
• First Posted (ACTUAL): April 15, 2020

Study Record Updates

• Last Update Posted (ACTUAL): May 11, 2022
• Last Update Submitted That Met QC Criteria: May 10, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: STEMI; NSTEMI; myocardial strain,; arterial stiffness,; lipid-lowering therapy,; electrical myocardial heterogeneity
• Additional Relevant MeSH Terms: Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Myocardial Infarction; Infarction; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites; Anticholesteremic Agents; Hypolipidemic Agents; Lipid Regulating Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Atorvastatin; Ezetimibe
• Other Study ID Numbers: PSU/T-471

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No